Immunomedics Warns Biosimilar Chasers Over Trodelvy
Sacituzumab Biologic Brand Was Approved By FDA In April
Biosimilar sponsors know well the challenges to approval. Immunomedics, which in April obtained FDA approval for the Trodelvy oncology biologic, has suggested the barriers for competitors to the brand may be insurmountable for some time.
